Walden Group Arranges the sale of Argentum Medical, LLC to Shore Capital Partners

admin

The Walden Group is pleased to announce that it represented Argentum Medical, LLC, an advanced woundcare company, in its sale of equity to Shore Capital Partners. Argentum’s core platform technology, Silverlon, is a uniquely designed silver-plated nylon matrix that releases potent silver ions into the wound without staining the skin or increasing bioburden. Validated by several clinical studies, Silverlon dressings …

EQT (Private Equity) Sells BSN Medical to Svenska Cellulosa Aktiebolaget (SCA)

waldengroup

Sweden’s Svenska Cellulosa Aktiebolaget (SCA), $12.3b global hygiene and forest products company, is buying BSN Medical GmbH, a Germany-based manufacturer of woundcare, noninvasive orthopedic and compression therapy products. The deal weights SCA’s business more toward healthcare. BSN has a major share in several attractive medical product markets and provides SCA with a new growth platform with future industry consolidation opportunities. About 85% of SCA’s sales derives from its hygiene business and about 15% from forest products, which it intends to spinoff to shareholders. Earlier,…

J&J to buy Abbott Medical Optics for $4.3b.

waldengroup

Johnson & Johnson (NYSE: JNJ), a $74.3b manufacturer of pharmaceuticals, medical devices and consumer healthcare products, has agreed to buy Abbott Medical Optics Inc, a global ophthalmic surgical and eye care products company and a unit of Abbott Labs. The deal greatly expands J&J’s $7b eye care segment, by adding ophthalmic products across three business segments — cataract surgery, laser refractive surgery, and consumer eye health (multipurpose contact lens and other solutions). Gives J&J the second…

Abbott is buying St.Jude Medical Further Consolidating the Medical Device Sector

waldengroup

Abbott Laboratories (NYSE:ABT), a $20.4b maker of diagnostics, medical devices, pharmaceuticals and nutritionals, has agreed to buy St. Jude Medical Inc. (NASDAQ:STJ), a major maker of devices for cardiac rhythm management, cardiovascular, and atrial fibrillation. St. Jude Medical’s strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management complement Abbott’s leading positions in coronary intervention and transcatheter mitral repair. With combined annual sales of ~$8.7b,…

What to Expect for 2016 Healthcare M&A Activity

waldengroup

Recent volatility in worldwide markets, weakness in China, terrorism, softness in Europe and emerging markets, budget issues, and healthcare reform dislocations are among the dynamics that have clouded the 2016 picture for healthcare M&A. Here, we help clarfty things.

.China.China is moving from a manufacturing and investment orientation to a consumption/consumer-based economy.The economy is still over-regulated and political freedoms are tight.Yet, China is going through a long-term, inexorable transition.The torrid growth rate has slowed to about 6.5% and stock market circuit breakers awkwardly kick in to prevent radical price swings,

Walden Advises Halma plc (LSE:HLMA) in its acquisition of Visiometrics, S.L. (Barcelona, Spain)

waldengroup

The Walden Group is pleased to announce that it has advised Halma plc, a UK-based public company, in its acquisition of Visiometrics, S.L., located outside Barcelona, Spain. On Halma’s behalf, The Walden Group identified Visiometrics as a strategic fit, cultivated a relationship with Visiometrics’ principals, advised Halma on the transaction, and assisted in its completion.

Medtronic’s 2015 Deal Appetite Whetted By Tax Savings

waldengroup

Medtronic’s most recent acquistion target was Lazarus Effect, a maker of stroke diagnostic devices. After obtaining European approval, Lazarus Effect is working to get U.S. approval for the ReCover brain blot clot removal device, which works with Medtronic ‘s Solitaire stent that can be deployed in the brain to scoop out vessel-blocking clots that cause acute ischemic stroke. ReCover removes clots from the brain using a “novel nitinol ‘mesh cover’ that folds over a stent retriever device during clot retrieval and ‘candy wraps’ the stent with the clot inside

VasSol Ushers in a New Stroke Diagnostic Standard of Care

waldengroup

The Journal of the American Medical Association – Neurology (JAMA Neurology) has indicated it will publish the results of the landmark stroke diagnostic study – VERiTAS (Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke study (VERiTAS).  Acceptance by this highly prestigious and influential peer-reviewed journal is a significant reflection of the importance of the study and the wide-ranging implications of the NOVA blood flow non-invasive MRI-based, objective stroke diagnostic system.

Aesthetic Surgery Market Trends – 2015

waldengroup

Key factors “shaping” the aesthetic surgery market and healthcare M&A activity in it are:

Large and Growing Market
15.6 million cosmetic procedures, including both minimally-invasive and surgical, were performed in the US in 2014, an increase of 3% since 2013. Additionally, 5.8 million reconstructive surgery procedures were performed last year, up 1%.

Allergan buys AqueSys, a maker of minimally invasive glaucoma surgery products, for $300m+

waldengroup

The deal provides Allergan with AqueSys’s minimally invasive glaucoma surgery (MIGS) device called the XEN45 Gel Stent.  MIGS devices are alternatives to glaucoma medication and more invasive surgical techniques.  The leader in the MIGS area is Glaukos, which closed an IPO in June 2015 and now has a market cap of over $1b.  Its iStent is FDA-approved for moderate to severe glaucoma while the AqueSys device is for mild to moderate patients.